Omega-3

Quick Summary

Omega-3 is not one substance — it is a family of three polyunsaturated fatty acids that behave very differently in the body.

• EPA (eicosapentaenoic acid, C20:5 n-3) is the omega-3 most strongly associated with anti-inflammatory effects, cardiovascular event reduction (in specific high-risk populations), and mood support. It is found in marine animals (fish, shellfish) and certain marine microalgae.
• DHA (docosahexaenoic acid, C22:6 n-3) is a structural fatty acid that makes up roughly 40% of the phospholipids in the human brain and around 50% of the polyunsaturated fatty acids in the outer-segment membranes of retinal rod cells. It is essential during pregnancy, infancy, and across the lifespan for maintenance of brain and visual function. DHA is found in fatty fish and in marine microalgae (the original source — fish acquire DHA by eating algae).
• ALA (α-linolenic acid, C18:3 n-3) is the plant-based omega-3 (flax, chia, walnuts, perilla, soybean and canola oils). ALA is an essential fatty acid — the human body cannot manufacture it — but the body converts ALA into EPA and DHA only in small amounts. Whole-body ALA-to-DHA conversion in most adults is below 5%, with substantial sex differences. ALA is valuable on its own but cannot fully substitute for EPA and DHA for outcomes that require the long-chain forms.

What the human-evidence record actually shows (high-quality meta-analyses and large randomized trials):

• Triglyceride lowering — robust, dose-dependent reduction of 15–30% in serum triglycerides at 2–4 g/day EPA+DHA (meta-analysis of randomized controlled trials, PMID 37264945).
• Cardiovascular event reduction is conditional, not universal. A 4 g/day pure-EPA prescription medication (icosapent ethyl) reduced major cardiovascular events by 25% in statin-treated patients with elevated triglycerides (REDUCE-IT, PMID 30415628). A 1 g/day EPA+DHA combination did not reduce total major cardiovascular events in a general adult population over 5.3 years (VITAL, PMID 30415637). A 4 g/day EPA+DHA carboxylic-acid combination did not reduce cardiovascular events and increased the risk of atrial fibrillation (STRENGTH, PMID 33190147). These three findings must be read together — they do not contradict each other; they tell us that dose, form, EPA-to-DHA ratio, and baseline risk all matter.
• Brain and cognition — DHA supports memory function in older adults with mild memory complaints (meta-analysis, PMID 25786262), but supplementation does not reverse established Alzheimer's disease in randomized controlled trials.
• Inflammation and rheumatoid arthritis — meta-analysis found omega-3 (EPA+DHA) significantly reduced tender joint count and improved inflammatory markers, while the composite DAS28 disease-activity change did not reach significance (PMID 38922552).
• Pregnancy — pregnancy omega-3 (LC-PUFA) supplementation lowers the risk of early preterm birth before 34 weeks gestation (Cochrane systematic review, PMID 30480773); DHA specifically is essential for fetal brain and retinal development (≥200 mg/day).
• Depression — meta-analyses support an antidepressant signal for EPA-predominant formulations (≥60% EPA) at roughly 1 g/day or below; DHA-predominant formulations do not show benefit (PMID 31383846 and PMID 26978738).
• Eye health is sub-domain specific — moderate evidence supports symptomatic relief in dry-eye disease; omega-3 does not prevent or slow age-related macular degeneration (AMD) in Cochrane and the AREDS2 trial.

General-adult intake guidance: Most public-health bodies endorse a minimum of about 250–500 mg/day EPA+DHA from diet or supplements for general maintenance. The U.S. Food and Drug Administration recommends that supplements not provide more than 2 g/day EPA+DHA, and considers total intake up to 3 g/day generally safe; the European Food Safety Authority concludes that intakes up to about 5 g/day in adults are not associated with adverse safety signals when consumed long-term. Doses of 4 g/day or higher have been associated with a small but consistent increase in atrial fibrillation risk and should be used under medical supervision, particularly in people with heart-rhythm disorders.

Bottom line for the casual reader: Omega-3 is genuinely beneficial — but its benefits are specific, dose-dependent, and form-dependent. Choose a quality product (third-party certified, fresh, with EPA and DHA milligrams clearly disclosed) and match the dose and EPA:DHA ratio to your reason for taking it.

What is Omega-3? Chemistry, conversion, and food sources

Omega-3 is not one substance but a family of three polyunsaturated fatty acids — EPA, DHA, and plant-based ALA — and whole-body ALA-to-DHA conversion is below 5% in most adults.

Omega-3 fatty acids are polyunsaturated fatty acids (PUFAs) with a double bond at the third carbon from the methyl end of the chain. The three nutritionally important members are EPA, DHA, and ALA.

EPA, DHA, and ALA at a glance

ALA-to-EPA-to-DHA conversion: the central question for plant-based diets

The single most-misunderstood point about omega-3 is whether eating plant-based ALA — for example flaxseed oil — is equivalent to consuming EPA and DHA directly. It is not. The human body converts only a small fraction of dietary ALA into EPA and DHA, and the efficiency varies considerably by sex, hormonal status, background diet, and individual genetics.

Conversion efficiency from isotope-tracer studies in adults:

Key takeaways from a generation of conversion research (summarized in the NIH Office of Dietary Supplements professional fact sheet and in the Burdge–Calder isotope-tracer series):

• Whole-body ALA-to-DHA conversion is below 5% in most adults.
• Premenopausal women convert substantially more ALA than men do. The leading mechanistic explanation is that estrogen upregulates hepatic Δ6-desaturase activity — biologically plausible because pregnancy and lactation create a large DHA demand for fetal and infant brain development. After menopause, female conversion drops toward male levels.
• Background diet matters. The omega-6 fatty acid linoleic acid (LA) competes with ALA for the same Δ6-desaturase enzyme. Typical Western diets have an omega-6 to omega-3 ratio of roughly 15–20:1, well above the 4:1 ratio often suggested as physiologically favorable; high LA intake suppresses ALA-to-EPA/DHA conversion in controlled human trials.
• Cofactors matter. Δ6 and Δ5 desaturase activity depends on zinc, magnesium, vitamin B3, vitamin B6, biotin, and vitamin C. Marginal deficiency of any of these reduces conversion.
• Genetics matter. Common variants in the FADS1 and FADS2 genes (which encode the desaturase enzymes) produce 3- to 5-fold individual differences in conversion efficiency.

Practical implications for plant-based eaters:

• An adult vegan or vegetarian trying to reach the 250 mg/day DHA threshold endorsed by the European Food Safety Authority for cardiovascular and cognitive maintenance through ALA alone would need to consume on the order of 25 grams of ALA per day — roughly 100 grams of flaxseed oil. This is not a realistic dietary strategy. Algae oil — the original dietary source of DHA, produced from microalgae fermented in closed bioreactors — is the practical plant-based route to direct EPA and DHA.
• For pregnant or breastfeeding people, direct DHA (from fish oil or algae oil) is recommended rather than relying on ALA conversion. The World Health Organization and the International Society for the Study of Fatty Acids and Lipids endorse at least 200 mg/day DHA during pregnancy and lactation.
• For infants and toddlers, endogenous DHA synthesis is insufficient for the rapid neural and retinal development of the first two years of life. Breast milk, DHA-fortified formula (the DHA in infant formula is sourced from algae), or direct DHA supplementation is the standard.

Why omega-3 is an "essential" fatty acid

Mammals cannot insert a double bond at the n-3 position of a fatty acid — we lack the enzymatic machinery to do so. ALA must therefore come from food. Once consumed, ALA serves as the substrate for some EPA and DHA synthesis, but the efficiency is low enough that direct dietary EPA and DHA (from fish, shellfish, or marine algae) are practically essential as well for outcomes that depend on adequate long-chain omega-3 status — including infant neural development, retinal health, cardiovascular event reduction, mood regulation, and resolution of inflammation.

Common dietary sources of preformed long-chain omega-3 in approximate descending order of EPA+DHA per serving include: salmon, mackerel, sardines, herring, anchovies, trout, oysters, mussels, krill, and certain seaweeds. ALA sources include flaxseed, chia, hemp, walnut, perilla, soybean and canola oils, and many leafy greens (in small amounts).

Mechanism of Action

EPA and DHA work through several converging mechanisms — membrane phospholipid incorporation, specialized pro-resolving mediators, eicosanoid competition with arachidonic acid, NF-κB suppression, GPR120 activation, and PPAR-α-driven triglyceride reduction.

Omega-3 fatty acids exert their effects through several converging molecular mechanisms. Reviewing them helps explain why the same nutrient appears in evidence reviews for cardiovascular, neurological, ophthalmic, immune, reproductive, and mood-related outcomes.

1 · Membrane phospholipid incorporation and modulation of membrane biophysics. EPA and DHA are incorporated into the phospholipids of cell membranes, partially displacing arachidonic acid (an omega-6 fatty acid). This changes membrane fluidity, the composition of lipid rafts, and the function of membrane-embedded receptors. DHA's prominence in the central nervous system (≈40% of brain phospholipid PUFA) and in the retina (≈50% of rod outer-segment PUFA) reflects this structural role, which is why adequate DHA intake is non-negotiable during periods of rapid neural growth (pregnancy, infancy, early childhood) and is supportive of maintenance across the lifespan.

2 · Specialized pro-resolving mediators (SPMs). EPA and DHA are precursors for a family of lipid signaling molecules — resolvins, protectins, and maresins — that actively terminate inflammation rather than merely suppressing it. EPA gives rise to E-series resolvins (RvE1, RvE2) and 18-HEPE. DHA gives rise to D-series resolvins (RvD1 through RvD6), protectin D1, and maresin 1. SPMs promote neutrophil clearance, macrophage efferocytosis (the orderly removal of dying cells), and tissue homeostasis. This is the molecular basis for omega-3's effects on rheumatoid arthritis, inflammatory bowel disease, and chronic low-grade inflammation.

3 · Competition with arachidonic acid in eicosanoid synthesis. EPA competes with arachidonic acid for the cyclooxygenase (COX-1 and COX-2) and lipoxygenase (LOX) enzymes. The eicosanoids produced from EPA (3-series prostaglandins, 3-series thromboxanes, 5-series leukotrienes) are markedly less pro-inflammatory than the arachidonic-acid–derived 2-series prostaglandins (including PGE₂) and 4-series leukotrienes (including LTB₄). This is the classic acute-anti-inflammatory mechanism.

4 · NF-κB pathway suppression. EPA and DHA inhibit IκB kinase activity, which prevents the NF-κB p65 transcription factor from translocating into the nucleus. The downstream result is reduced transcription of pro-inflammatory cytokines (IL-6, TNF-α, IL-1β) and C-reactive protein — the molecular fingerprint of chronic low-grade inflammation, sometimes called "meta-inflammation," that links obesity, type 2 diabetes, atherosclerosis, and several other conditions.

5 · GPR120/FFAR4 receptor activation. DHA and EPA are high-affinity endogenous ligands for the G-protein–coupled receptor GPR120 (also called FFAR4). Activation of macrophage GPR120 suppresses TLR4 and TNF-receptor signaling, improves insulin sensitivity in adipose tissue, and contributes to systemic anti-inflammatory effects.

6 · PPAR-α activation and triglyceride reduction. EPA and DHA activate the nuclear receptor PPAR-α, upregulating hepatic β-oxidation genes and suppressing SREBP-1c, the master transcriptional regulator of de novo lipogenesis. The downstream effect is reduced hepatic VLDL synthesis and accelerated clearance of circulating triglycerides — the most reproducible metabolic effect of omega-3 in human trials, with consistent dose-dependent reductions of 15–30% in serum triglycerides at 2–4 g/day EPA+DHA.

7 · Neurotransmitter modulation and BDNF support. EPA influences serotonin and dopamine signaling; DHA upregulates brain-derived neurotrophic factor (BDNF). These pathways provide the neurobiological context for omega-3's effects on mood and cognition.

The mechanistic case for omega-3 is supported by human biomarker data (red-blood-cell membrane Omega-3 Index, circulating SPMs, inflammatory cytokines), tissue biopsy data (adipose, cardiac, brain), and animal knockout models. The mechanistic evidence is unusually strong by supplement-science standards; the open questions concern which mechanism dominates in which clinical context, not whether the mechanisms exist.

Evidence-Based Benefits

The omega-3 evidence record is large, mature, and — uniquely among popular supplements — contains several major negative or null randomized controlled trials alongside positive findings. This page presents both, in the transparency tradition of NIH-ODS, Cochrane, and Examine.com. Each sub-section indicates the evidence tier (A = strong/consistent, B = moderate, C = preliminary), the strongest individual studies, and the relevant limitations.

Dosage by Context

General maintenance is roughly 250–500 mg/day EPA+DHA; the FDA guidance is ≤2 g/day EPA+DHA from supplements (total intake up to 3 g/day considered safe) and EFSA recognizes intakes up to ~5 g/day, with atrial-fibrillation risk rising at 4 g/day or higher.

The right dose depends on the outcome you are targeting, your baseline diet, and (especially at higher doses) any medical conditions you have. The table below summarizes the dose ranges supported by the strongest randomized-trial and meta-analytic evidence cited in the Benefits section above.

Key dose caveats.

• The FDA "qualified health claim" pathway for cardiovascular disease requires at least 0.8 g of EPA+DHA per serving.
• EFSA recognizes specific health claims at 250 mg/day EPA+DHA (cardiovascular and brain), 200 mg/day DHA (maintenance of normal brain function), and 200 mg/day DHA (during pregnancy, fetal and maternal brain and eye development).
• Brazil's ANVISA (IN 28/2018 Anexo V) authorizes two functional claims for omega-3 supplements — "source of omega-3" and an EPA+DHA triglyceride-reduction claim — the latter requiring at least 1,500 mg combined EPA+DHA per daily serving.
• In China, algae DHA/EPA oil (Schizochytrium) is an approved Novel Food (National Health Commission) and fish oil is a conventional food; omega-3 is additionally used in NMPA-registered health-food products for the blood-lipid-regulation function.
• At doses of 4 g/day or higher, the risk of atrial fibrillation is increased. This is reproducible (REDUCE-IT and STRENGTH both reported it; STRENGTH more strongly). High-dose omega-3 should be used under physician supervision, particularly in people with a history of atrial fibrillation or other heart-rhythm disorders.
• EPA-vs-DHA ratio is not cosmetic. A "1,000 mg fish oil" softgel can contain anywhere from 120 mg to 800 mg of actual EPA+DHA, and the EPA:DHA ratio can range from heavily DHA-skewed (algae) to heavily EPA-skewed (anti-inflammatory or mood-targeted products). Match the ratio to your reason for taking it.

Safety, Side Effects, and Drug Interactions

Common, mild side effects include a fishy-taste reflux or belching (especially with lower-purity products taken on an empty stomach), gastrointestinal discomfort (nausea, loose stools, bloating), and occasional epistaxis at higher doses. Most side effects are dose-dependent and form-dependent; high-quality rTG forms taken with a meal substantially reduce reflux.

Atrial fibrillation at high dose. As detailed in the Cardiovascular and Negative Findings sections above, doses of 4 g/day EPA+DHA have been associated with an approximately 1% absolute increase in atrial-fibrillation incidence in the STRENGTH trial, with a smaller but reproducible signal in REDUCE-IT. People with a history of atrial fibrillation, atrial flutter, or other heart-rhythm disorders should use high-dose omega-3 only under medical supervision.

Bleeding risk. Omega-3 inhibits platelet aggregation in laboratory and short-term human studies. The American Heart Association's 2017 scientific statement and subsequent reviews concluded that clinically important bleeding has not been demonstrated in randomized trials of omega-3 at supplemental doses, including in patients on anticoagulants (warfarin, direct oral anticoagulants) and antiplatelet agents (aspirin, clopidogrel) and including in the peri-operative period. The theoretical concern remains, and patients taking anticoagulants in combination with high-dose omega-3 should inform their physician and have routine monitoring.

Drug interactions.

• Antihypertensives: mild additive blood-pressure lowering. Helpful in most settings; clinically relevant in patients near hypotension.
• Statins: combination is safe and is the explicit context of the REDUCE-IT trial.
• Antidiabetic medications: mild additive glucose-lowering effect possible.
• Anticoagulants and antiplatelet agents: see "Bleeding risk" above — clinically important bleeding has not been demonstrated, but monitoring is reasonable.

Allergy. People with fish or shellfish allergy should avoid fish-derived and krill-derived oils and use algae oil instead. Algae oil is produced by fermentation of marine microalgae in closed bioreactors and has no protein cross-reactivity with fish or shellfish allergens.

Pregnancy and breastfeeding. DHA supplementation at 200–300 mg/day during pregnancy and lactation is recommended by the World Health Organization and the International Society for the Study of Fatty Acids and Lipids. Randomized-trial safety data are extensive (including the 70-trial Cochrane review). During pregnancy, prefer products that are tested for low mercury, polychlorinated biphenyls (PCBs), and dioxins, or use algae oil, which is produced in closed-system fermentation and is free of marine contaminants.

Infants and toddlers. DHA is required for normal neural and retinal development; endogenous synthesis is insufficient. The DHA in standardized infant formula is sourced from algae and is well established.

Heavy metals and persistent organic pollutants. Crude fish oil can carry mercury, PCBs, dioxins, and other contaminants from contaminated waters. Modern refined and molecularly distilled fish oils typically test below detection limits for these contaminants, and third-party certifications (described in Quality section below) verify this. Algae oil produced by closed-system fermentation does not encounter the marine pollutant chain and is structurally free of these concerns.

Oxidation (rancidity). Long-chain omega-3 fatty acids are highly unsaturated and oxidize readily. The Global Organization for EPA and DHA (GOED) voluntary monograph recommends a TOTOX value (a combined measure of peroxide and anisidine values) of ≤26. A fishy after-taste, an unpleasant odor on opening a softgel, or "off" flavor indicate oxidation and reduced product quality.

Cod liver oil — a specific case. Cod liver oil contains high levels of vitamins A and D in addition to EPA+DHA. Pregnant people and others should avoid stacking cod liver oil with separate vitamin A supplementation; for general EPA+DHA support, a refined fish oil or algae oil is preferable.

Forms Comparison — rTG, TG, EE, and PL

User searches for "rTG vs EE," "best omega-3 form," and "ethyl ester vs triglyceride" are among the highest-intent queries on the topic. The four chemical forms below differ in their bioavailability and in their typical product context.

The four main forms

Bioavailability — what head-to-head trials show

Bioavailability is conventionally measured by the rise in plasma EPA+DHA (and, in longer studies, the rise in red-blood-cell membrane Omega-3 Index) after consuming a defined dose. The most-cited head-to-head study (Dyerberg et al. 2010, PMID 20638827, Prostaglandins Leukotrienes and Essential Fatty Acids) reported the following relative plasma area-under-the-curve, with natural TG fish oil taken as the 100% reference:

• rTG ≈ 124% of natural TG
• TG = 100% (reference)
• EE ≈ 73% of natural TG
• PL (krill) ≈ comparable plasma incorporation to TG and rTG on a per-mg-EPA+DHA basis in some studies (Yurko-Mauro et al. 2015, PMID 26328782), although the overall EPA+DHA content per softgel is typically lower

Subsequent head-to-head trials, including a 2023 sixteen-week randomized intervention (Minton et al., PMID 36706088), generally confirm that rTG and natural TG forms achieve higher plasma incorporation than EE on an empty stomach, with the rTG advantage over EE typically in the range of 1.3- to 1.7-fold.

Meal effect — the great equalizer

EPA and DHA are fat-soluble and require bile acids and pancreatic lipase for absorption. Taking any form of omega-3 with a meal — especially one containing at least about 15 grams of fat — substantially improves absorption.

• Empty stomach: EE shows the largest disadvantage relative to TG and rTG.
• With a fat-containing meal: the gap between EE and TG/rTG narrows substantially, and EE achieves bioavailability comparable to TG.

The practical guidance for any form: take omega-3 with the largest fat-containing meal of the day.

Krill oil and phospholipid forms — a separate conversation

Krill oil delivers EPA and DHA primarily in phospholipid form (mostly phosphatidylcholine), along with a small amount of naturally occurring astaxanthin (a marine carotenoid). Per milligram of EPA+DHA, krill oil shows competitive plasma incorporation in several studies. However, the overall EPA+DHA concentration in krill oil is markedly lower than in concentrated fish oil, so a given softgel of krill oil typically delivers substantially less EPA+DHA than a concentrated rTG fish-oil softgel. Krill oil is also more expensive per milligram of EPA+DHA and carries shellfish-allergy cross-reactivity considerations. The sub-page Krill Oil covers these trade-offs in detail and is cross-linked with the live Astaxanthin page, which examines the carotenoid independently of its role as a co-occurring ingredient in krill products.

How to choose a quality omega-3 product

Independent of form, the following criteria help readers evaluate any omega-3 product on the market.

1. Third-party purity certification. Look for IFOS (International Fish Oil Standards), USP Verified, or NSF certification. These independent programs test the actual product — not just the label — for mercury, PCBs, dioxins, heavy metals, oxidation markers, and the accuracy of the EPA+DHA milligram declaration.
2. Form transparency on the label. Most products on the market do not state whether their omega-3 is in TG, rTG, or EE form. A quality product discloses the form.
3. EPA and DHA milligram disclosure, not "fish oil milligrams." "1,000 mg fish oil" tells you very little. The label that matters is "X mg EPA, Y mg DHA per serving." A reputable product makes both numbers easy to find on the supplement-facts panel.
4. Freshness markers. TOTOX value of 26 or below (the GOED voluntary monograph upper limit) and peroxide value of 5 milliequivalents per kilogram or below are typical quality thresholds. A fishy after-taste, a strong "off" smell, or visible degradation in softgels suggests oxidation.
5. Sustainability certification, where it applies. For fish-derived products, MSC (Marine Stewardship Council) certification indicates that the source fishery is managed under independent sustainability standards. For algae oil, closed-system fermentation avoids wild-fishery extraction entirely.
6. EPA:DHA ratio matched to use case. A high-DHA product (algae, marketed for pregnancy or cognitive support) is not the same product as a high-EPA product (marketed for cardiovascular event reduction or mood support). Buy the ratio that matches your reason for taking it.
7. Reasonable dose disclosure. A product that requires six softgels per day to reach 1 g of EPA+DHA is not necessarily a bad product, but a single softgel delivering the same dose is more practical for adherence.

These criteria are intentionally generic and apply across brands. They are the same criteria used by NIH-ODS, Examine.com, and Cleveland Clinic in consumer-facing guidance.

Sources — Fish Oil, Algae Oil, Krill Oil, and ALA Sources

Omega-3 is sourced from four broad categories of organisms, each with different EPA:DHA ratios, sustainability characteristics, and best-fit user populations. This page treats sources at an overview level; each source has a dedicated sub-page (forthcoming in this cluster) with deeper detail.

A note on choosing a source. Omega-3 is not one ingredient — it is a family of fatty acids sourced from different organisms, each with distinct strengths and trade-offs. Choose a source based on dietary preference, life stage, sustainability priority, and the specific health outcome you are supporting. For most general adults, a third-party-certified rTG fish oil from a small-fish source (anchovy, sardine, mackerel) provides the best combination of evidence base, concentration, and cost. For plant-based eaters, pregnant and breastfeeding people, and users prioritizing sustainability or avoiding marine contaminants, algae oil is the more appropriate primary source. Flaxseed and other ALA sources are useful background omega-3 in any diet but should not be the sole source for users who depend on long-chain omega-3 outcomes.

Quality, Purity, and Sustainability

Omega-3 product quality varies more than most categories of supplement, because long-chain polyunsaturated fatty acids are inherently prone to oxidation, and because crude marine sources can carry pollutants. The information below is generic to the category and applies across brands.

Third-party purity certifications

A reasonable buying heuristic: look for at least one third-party purity certification (IFOS, USP, or NSF) on the label or on the manufacturer's website. Sustainability certification (MSC for wild-caught fish, or closed-system fermentation for algae oil) is an additional layer.

Typical contaminant upper limits (reference values)

Sustainability considerations

Approximately three-quarters of global fish oil production is used in aquaculture feed, which in turn supports farmed-fish production. This dual demand creates pressure on the small-pelagic forage-fish stocks (anchovy, sardine, menhaden) that supply most of the world's omega-3. The sustainability picture is nuanced:

• MSC-certified fisheries and short-lived small-fish sources (anchovy, sardine, mackerel, herring) — species low on the food chain with rapid reproduction and minimal bioaccumulation of heavy metals — are generally the more sustainable fish-oil category.
• Larger predator fish (tuna, swordfish, shark) are not used for supplement-grade fish oil but do bioaccumulate heavier loads of mercury and persistent organic pollutants.
• Antarctic krill is a keystone species in the Southern Ocean food web (a primary food source for whales, penguins, and seals). Krill fisheries are regulated by the Commission for the Conservation of Antarctic Marine Living Resources (CCAMLR), but expansion of the krill harvest is contested by some conservation organizations.
• Algae oil, produced by fermentation of microalgae in closed bioreactors, does not draw on wild-fishery resources at all. It is the structurally lowest-impact source of EPA and DHA. As fermentation costs decline and EPA-enriched algae strains become more widely available, algae oil's share of the omega-3 supply is expected to grow.

For readers prioritizing sustainability or avoiding marine contaminants, third-party-certified algae oil — or third-party-certified, MSC-certified, small-fish-source rTG fish oil — represents the most defensible choice. Larger-predator-fish oil and krill oil are reasonable for users with specific reasons to choose them but are less defensible as default sustainability picks.

Cluster Sub-pages (upcoming)

This cluster hub covers the omega-3 family at an overview level. Each source organism has a dedicated sub-page with deeper detail on chemistry, manufacturing, evidence base, and trade-offs:

• Fish Oil — Highest concentration · deepest evidence base · small-fish sources (anchovy/sardine/mackerel) preferred
• Algae Oil — Plant-based · the original dietary source of DHA · closed-system fermentation · pregnancy/vegan preferred
• Krill Oil — Phospholipid form · co-occurring astaxanthin · lower total EPA+DHA per softgel · shellfish allergy caution
• Flaxseed / ALA Sources — ALA only · whole-body conversion to DHA <5% in most adults · not a substitute for long-chain EPA/DHA

Frequently Asked Questions

The questions below are the most-searched questions on omega-3 across general web search and AI assistants. Answers reflect the evidence cited throughout this page and are intentionally concise; deeper detail lives in the relevant sections above.

Tags

Body Systems: Cardiovascular · Neurological & Cognitive · Vision · Immune System · Musculoskeletal · Mood & Stress Response · Reproductive

Mechanisms: NF-κB signaling inhibition · Specialized pro-resolving mediators (SPMs) biosynthesis · Cell membrane phospholipid integration · PPAR-α activation · Neurotransmitter modulation · GPR120 receptor activation · Competitive metabolism with arachidonic acid

Evidence Tier: Meta-analysis supported

Dosage Range: 250-2000 mg/d EPA+DHA (general · context-dependent · up to 4 g/d under medical supervision · ≤2 g/d EPA+DHA from supplements per FDA (total intake up to 3 g/d considered safe) · ≤5 g/d EFSA tolerable upper)

Last Evidence Review: 2026-05-24 · Reviewed by Evidence Synthesis Lead + Regulatory Compliance Lead

Related Goals

• heart-health
• cognitive-support
• longevity-stack
• inflammation-relief
• eye-protection
• reproductive-health
• menopause-support

Related Lifestyles

• plant-based
• pregnancy
• athletic-performance
• senior-60-plus

Related Ingredients

• fish-oil
• algae-oil
• krill-oil
• ala
• astaxanthin
• vitamin-d3

Read the Evidence (deep dive long-form)

For a deep-dive narrative on omega-3 cardiovascular evidence chronology (DART → GISSI → JELIS → REDUCE-IT → STRENGTH + inflammation + cognition + women's health endpoints), see the dedicated evidence article:

• Omega-3 Evidence History — Cardiovascular, Inflammation and Beyond — 28 PMID-anchored citations · 6 landmark cardiovascular RCTs (DART / GISSI-Prevenzione / JELIS / ORIGIN / Risk and Prevention / ASCEND) · inflammation + mood + women's health clusters · peer cross-link to Natural-vs-Synthetic Astaxanthin for shared cardiovascular + lipid-metabolism endpoints.

Cross-reading the long-form evidence article alongside this fact sheet builds the holistic omega-3 evidence picture from DART-era epidemiology → modern RCT chronology → Cochrane meta-analysis nulls → SPM mechanism framing.

References

All PMIDs verified by upstream evidence document (2026-05-24). Effect sizes are reported as published. The upstream evidence document includes the full extraction provenance and the the Omega-3 source dossier cross-reference.

Cardiovascular Outcomes

1. PMID 30415628 · Bhatt DL et al. (2019) · "Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia" (REDUCE-IT) · NEJM · n=8,179 statin-treated · 4 g/day pure EPA · primary CV composite HR 0.75 (-25%) over 4.9 y
2. PMID 30415637 · Manson JE et al. (2019) · "Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer" (VITAL) · NEJM · n=25,871 generally healthy · 1 g/day EPA+DHA · primary CV null (HR 0.92) · MI -28% secondary
3. PMID 33190147 · Nicholls SJ et al. (2020) · "Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events" (STRENGTH) · JAMA · n=13,078 statin-treated high-risk · 4 g/day EPA+DHA CA · primary null + AF HR ~1.69
4. PMID 37264945 · Triglyceride dose-response meta-analysis · 2–4 g/day EPA+DHA → 15–30% serum triglyceride reduction

Brain and Cognition

5. PMID 25786262 · Yurko-Mauro K et al. (2015) · DHA / DHA+EPA memory function meta-analysis in older adults with mild memory complaints · PLOS ONE
6. PMID 38468309 · 2024 dose-response meta-analysis · omega-3 PUFA cognitive outcomes in adults without dementia · BMC Medicine
7. PMID 38924283 · Calderon Martinez et al. (2024) · meta-analysis of RCTs in diagnosed Alzheimer's disease · no cognitive improvement
8. PMID 28986068 · Araya-Quintanilla et al. (2020) · meta-analysis of RCTs in diagnosed AD · no disease reversal

Inflammation / Joint

9. PMID 38922552 · Wang et al. (2024) · meta-analysis of RCTs in rheumatoid arthritis · DAS28 + inflammatory markers + NSAID use reduction · Clinical Rheumatology
10. PMID 17335973 · Goldberg & Katz (2007) · meta-analysis of 17 RCTs in inflammatory joint pain (RA · IBD · dysmenorrhea) · authors' "treated with some caution" caveat · Pain

Pregnancy

11. PMID 30480773 · Middleton P et al. (2018) · "Omega-3 fatty acid addition during pregnancy" · Cochrane Database of Systematic Reviews · 70 RCTs n=19,927 · early preterm <34 weeks -42%

Eye Health (AMD Null)

12. PMID 25856365 · Lawrenson JG, Evans JR (2015) · "Omega 3 fatty acids for preventing or slowing the progression of age-related macular degeneration" · Cochrane Database of Systematic Reviews · no benefit on AMD progression

Mood / Depression

13. PMID 31383846 · Liao Y et al. (2019) · meta-analysis of 26 RCTs n=2,160 · EPA-predominant (≥60%) ≤1 g/day antidepressant effect · DHA-predominant null · Translational Psychiatry
14. PMID 26978738 · Mocking RJT et al. (2016) · meta-analysis + meta-regression of 13 RCTs n=1,233 · higher EPA dose + concurrent antidepressant predict better outcomes · Translational Psychiatry
15. PMID 34493705 · 2021 correction to PMID 31383846

Forms / Bioavailability

16. PMID 20638827 · Dyerberg J et al. (2010) · "Bioavailability of marine n-3 fatty acid formulations" · Prostaglandins Leukotrienes and Essential Fatty Acids · rTG 124% · TG 100% · EE 73%
17. PMID 26328782 · Yurko-Mauro K et al. (2015) · krill phospholipid form per-mg comparable bioavailability
18. PMID 36706088 · Minton et al. (2023) · 16-week randomized intervention confirming rTG/TG > EE on empty stomach (1.3–1.7×)

Regulatory and Public-Health References (not counted in PMID total)

• FDA · Qualified health claim for EPA+DHA and coronary heart disease (≥0.8 g per serving) · supplement labels should not recommend exceeding 2 g/day EPA+DHA; total intake up to 3 g/day considered GRAS
• EFSA 2012 · Tolerable upper intake up to ~5 g/day EPA+DHA in adults · Article 13 nutrition claims (250 mg/day EPA+DHA cardiovascular and brain · 200 mg/day DHA brain function · 200 mg/day DHA pregnancy fetal brain/eye)
• ANVISA (Brazil) 2018 · RDC 243/2018 dietary supplement framework · IN 28/2018 Anexo V two authorized functional claims: "Fonte de ômega 3" and the EPA+DHA triglyceride-reduction claim (≥ 1,500 mg EPA+DHA/day)
• China NHC · Algae DHA/EPA oil (Schizochytrium) approved as a Novel Food; fish oil a conventional food; omega-3 also used in NMPA-registered health-food products for blood-lipid regulation
• WHO / ISSFAL · ≥200 mg/day DHA during pregnancy and lactation
• GOED Voluntary Monograph · TOTOX ≤26 · peroxide value ≤5 mEq/kg · contaminant limits
• AHA 2017 Scientific Statement · omega-3 bleeding risk · no clinically important bleeding demonstrated at supplemental doses

Educational Disclaimer

This page is educational reference content and is not medical advice. Discuss supplement use with a qualified healthcare provider, particularly if you are pregnant, breastfeeding, take prescription medications, or have a history of atrial fibrillation, bleeding disorders, or other medical conditions.